Estimated number of lives directly saved by COVID-19 vaccination programmes in the WHO European Region from December, 2020, to March, 2023: a retrospective surveillance study.

Autor:	Meslé MMI; World Health Organization Regional Office for Europe, Copenhagen, Denmark. Electronic address: meslem@who.int., Brown J; World Health Organization Regional Office for Europe, Copenhagen, Denmark., Mook P; World Health Organization Regional Office for Europe, Copenhagen, Denmark., Katz MA; World Health Organization Regional Office for Europe, Copenhagen, Denmark., Hagan J; World Health Organization Regional Office for Europe, Copenhagen, Denmark., Pastore R; World Health Organization Regional Office for Europe, Copenhagen, Denmark., Benka B; Österreichische Agentur für Gesundheit und Ernährungssicherheit, Vienna, Austria., Redlberger-Fritz M; Medical University, Vienna, Austria., Bossuyt N; Sciensano, Brussels, Belgium., Stouten V; Sciensano, Brussels, Belgium., Vernemmen C; Sciensano, Brussels, Belgium., Constantinou E; Medical and Public Health Services, Ministry of Health, Nicosia, Cyprus., Maly M; National Institute of Public Health, Prague, Czechia., Kynčl J; National Institute of Public Health, Prague, Czechia; Third Faculty of Medicine, Charles University, Prague, Czechia., Sanca O; Institute of Health Information and Statistics of the Czech Republic, Nové Město, Czechia., Krause TG; Statens Serum Institute, Copenhagen, Denmark., Vestergaard LS; Statens Serum Institute, Copenhagen, Denmark., Leino T; Finnish Institute for Health and Welfare, Helsinki, Finland., Poukka E; Finnish Institute for Health and Welfare, Helsinki, Finland., Gkolfinopoulou K; Hellenic National Public Health Organization, Athens, Greece., Mellou K; Hellenic National Public Health Organization, Athens, Greece., Tsintziloni M; Hellenic National Public Health Organization, Athens, Greece., Molnár Z; National Center for Public Health and Pharmacy, Budapest, Hungary., Aspelund G; Centre for Health Security and Communicable Disease Control, Reykjavik, Iceland., Thordardottir M; Centre for Health Security and Communicable Disease Control, Reykjavik, Iceland., Domegan L; Health Service Executive-Health Protection Surveillance Centre, Dublin, Ireland., Kelly E; Health Service Executive-Health Protection Surveillance Centre, Dublin, Ireland., O'Donell J; Health Service Executive-Health Protection Surveillance Centre, Dublin, Ireland., Urdiales AM; Istituto Superiore di Sanità, Rome, Italy., Riccardo F; Istituto Superiore di Sanità, Rome, Italy., Sacco C; Istituto Superiore di Sanità, Rome, Italy., Bumšteinas V; National Public Health Center under the Ministry of Health, Vilnius, Lithuania., Liausediene R; National Public Health Center under the Ministry of Health, Vilnius, Lithuania., Mossong J; Health Directorate, Luxembourg, Luxembourg., Vergison A; Health Directorate, Luxembourg, Luxembourg., Borg ML; Infectious Disease Prevention and Control Unit, Health Promotion and Disease Prevention Directorate, Pietà, Malta., Melillo T; Infectious Disease Prevention and Control Unit, Health Promotion and Disease Prevention Directorate, Pietà, Malta., Kocinski D; Institute of Public Health of Republic of North Macedonia, Skopje, North Macedonia., Pollozhani E; Institute of Public Health of Republic of North Macedonia, Skopje, North Macedonia., Meijerink H; Norwegian Institute of Public Health, Oslo, Norway., Costa D; Directorate of Disease Prevention and Health Promotion, Directorate-General of Health, Lisbon, Portugal., Gomes JP; National Health Institute Doutor Ricardo Jorge, Lisbon, Portugal., Leite PP; Directorate of Information and Analysis, Directorate-General of Health, Lisbon, Portugal., Druc A; National Agency for Public Health, Chisinau, Moldova., Gutu V; National Agency for Public Health, Chisinau, Moldova., Mita V; National Agency for Public Health, Chisinau, Moldova., Lazar M; Cantacuzino National Military Medical Institute for Research and Development, Bucharest, Romania., Popescu R; National Institute of Public Health, Bucureşti, Romania., Popovici O; National Institute of Public Health, Bucureşti, Romania., Musilová M; Regional Public Health Authority, Banská Bystrica, Slovakia., Mrzel M; National Institute of Public Health, Ljubljana, Slovenia., Socan M; National Institute of Public Health, Ljubljana, Slovenia., Učakar V; National Institute of Public Health, Ljubljana, Slovenia., Limia A; Ministry of Health, Madrid, Spain., Mazagatos C; Instituto de Salud Carlos III, Madrid, Spain., Olmedo C; Ministry of Health, Madrid, Spain., Dabrera G; UK Health Security Agency, London, UK., Kall M; UK Health Security Agency, London, UK., Sinnathamby M; UK Health Security Agency, London, UK., McGowan G; Public Health Scotland, Glasgow, UK., McMenamin J; Public Health Scotland, Glasgow, UK., Morrison K; Public Health Scotland, Glasgow, UK., Nitzan D; World Health Organization Regional Office for Europe, Copenhagen, Denmark., Widdowson MA; World Health Organization Regional Office for Europe, Copenhagen, Denmark., Smallwood C; World Health Organization Regional Office for Europe, Copenhagen, Denmark., Pebody R; World Health Organization Regional Office for Europe, Copenhagen, Denmark.
Jazyk:	angličtina
Zdroj:	The Lancet. Respiratory medicine [Lancet Respir Med] 2024 Sep; Vol. 12 (9), pp. 714-727. Date of Electronic Publication: 2024 Aug 07.
DOI:	10.1016/S2213-2600(24)00179-6
Abstrakt:	Background: By March, 2023, 54 countries, areas, and territories (hereafter CAT) in the WHO European Region had reported more than 2·2 million COVID-19-related deaths to the WHO Regional Office for Europe. Here, we estimated how many lives were directly saved by vaccinating adults in the WHO European Region from December, 2020, to March, 2023. Methods: In this retrospective surveillance study, we estimated the number of lives directly saved by age group, vaccine dose, and circulating variant-of-concern (VOC) period, regionally and nationally, using weekly data on COVID-19 mortality and infection, COVID-19 vaccination uptake, and SARS-CoV-2 virus characterisations by lineage downloaded from The European Surveillance System on June 11, 2023, as well as vaccine effectiveness data from the literature. We included data for six age groups (25-49 years, 50-59 years, ≥60 years, 60-69 years, 70-79 years, and ≥80 years). To be included in the analysis, CAT needed to have reported both COVID-19 vaccination and mortality data for at least one of the four older age groups. Only CAT that reported weekly data for both COVID-19 vaccination and mortality by age group for 90% of study weeks or more in the full study period were included. We calculated the percentage reduction in the number of expected and reported deaths. Findings: Between December, 2020, and March, 2023, in 34 of 54 CAT included in the analysis, COVID-19 vaccines reduced deaths by 59% overall (CAT range 17-82%), representing approximately 1·6 million lives saved (range 1·5-1·7 million) in those aged 25 years or older: 96% of lives saved were aged 60 years or older and 52% were aged 80 years or older; first boosters saved 51% of lives, and 60% were saved during the Omicron period. Interpretation: Over nearly 2·5 years, most lives saved by COVID-19 vaccination were in older adults by first booster dose and during the Omicron period, reinforcing the importance of up-to-date vaccination among the most at-risk individuals. Further modelling work should evaluate indirect effects of vaccination and public health and social measures. Funding: US Centers for Disease Control and Prevention. Competing Interests: Declaration of interests GD reports that the predecessor of the organisation he works for, Public Health England, received an unrestricted grant from GSK to undertake a study on the outcome of patients who received parenteral zanamavir. The funder received data and interim reports from Public Health England but did not influence analysis and reporting of the study. GD had no involvement in the GSK-funded study on parenteral zanamavir. Furthermore, the currently submitted work was part of the public health response activities to COVID-19 and had no relationship to GSK or the study on parenteral zanamivir. EP has received a personal grant from the Finnish Medical Foundation for PhD studies. JM declares that Public Health Scotland received funding from the EU Horizon 2020 programme for work in describing the epidemiology of COVID-19 and its impact on primary and secondary care as a partner in the IMOVE-COVID-19 project. MK declares having received consulting fees from Gilead Sciences for advising on development of a clinical module for collection of patient-reported outcome data from people living with HIV, and having received an honoraria from GESIDA for speaking at an annual conference on patient-reported outcome measures for people with HIV. All other authors declare no competing interests. (Copyright © 2024 World Health Organization. Published by Elsevier Ltd. All rights reserved, including those for text and data mining, AI training, and similar technologies.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu